KBP BioSciences Revenue and Competitors

Location

$76M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • KBP BioSciences's estimated annual revenue is currently $4.8M per year.(i)
  • KBP BioSciences received $76.0M in venture funding in January 2018.
  • KBP BioSciences's estimated revenue per employee is $100,500
  • KBP BioSciences's total funding is $76M.

Employee Data

  • KBP BioSciences has 48 Employees.(i)
  • KBP BioSciences grew their employee count by 7% last year.

KBP BioSciences's People

NameTitleEmail/Phone
1
Chief Development Officer/SVPReveal Email/Phone
2
CFOReveal Email/Phone
3
VP BiologyReveal Email/Phone
4
VP Human ResourcesReveal Email/Phone
5
VP, Regulatory & Medical AffairsReveal Email/Phone
6
VP, Project ManagementReveal Email/Phone
7
VP, Project ManagementReveal Email/Phone
8
Director Business DevelopmentReveal Email/Phone
9
Chief Operating Officer, Global Clinical Development, Global R&DReveal Email/Phone
10
Chief Financial OfficerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is KBP BioSciences?

At KBP we are consistently reminded that patient care is the end goal of what we do daily. Our discovery team is highly experienced in identifying new compounds with potential. The close interactions of the discovery and development teams result in a deep pipeline with multiple clinical and pre-clinical compounds. 2The major organ research group is focused on the maintenance and postponement of disease progression of three primary organ systems lung, heart, and kidney and is capable of assessing a drug's activity and active mechanism in both in vitro and in vivo models. 3The antimicrobial group, leverages a proprietary microbial bank comprised of 20,000+ clinically-isolated strains, including anaerobic bacteria and fungi, to evaluate internally generated drug candidates effectively. 1The immunology group conducts research on the roles of T- and B-cells in rheumatoid arthritis, hyperuricemia, idiopathic pulmonary fibrosis, among others. Our laser-focus on these three therapeutic areas provides powerful and unique insights on the underlying physiological and pathological processes that drive disease, opening up new avenues to tackle specific targets. Our researchers use their expertise to locate these new directions and exploit them, resulting in innovative therapies for a wide variety of illnesses. https://kbpbiosciences.com/aboutus/

keywords:N/A

$76M

Total Funding

48

Number of Employees

$4.8M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

KBP BioSciences News

2022-04-13 - Ansa Biotechnologies ties up $68M for DNA synthesis platform

He comes following previous CFO roles at Apollomics, KBP Biosciences and ... Endocrine-focused Spruce Biosciences is bringing on Libbie Mansell, Ph.D.,...

2022-04-06 - Kaleido calls it quits as its microbiome pipeline implodes

He comes following previous CFO roles at Apollomics, KBP Biosciences and SciCloneRelease. Release. Former head of Novatis' solid tumor oncology unit...

2022-03-30 - Tessa Therapeutics Appoints Wilson W. Cheung as Chief Financial ...

Cheung was CFO at KBP Biosciences, Inc. and served as SVP and CFO at SciClone Pharmaceuticals, Inc. where he led the sale of SciClone to a...

2018-01-08 - China: KBP Biosciences secures $76m Series A, launches global HQ in US

Premium China’s research-focussed biotech company KBP Biosciences has closed a $76 million Series A financing co-led by Advantech Capital and SDIC Venture Capital. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subscriber? Log in Contact us for corpor ...

2018-01-08 - China: KBP Biosciences secures $76m Series A, launches global HQ in US

Premium China’s research-focussed biotech company KBP Biosciences has closed a $76 million Series A financing co-led by Advantech Capital and SDIC Venture Capital. Continue reading this story with a subscription to DealStreetAsia. Subscribe Already a subscriber? Log in Contact us for corpor ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M484%N/A
#2
$5.6M484%N/A
#3
$3.8M48-16%N/A
#4
$15M48-6%N/A
#5
$12.9M49-11%N/A

KBP BioSciences Funding

DateAmountRoundLead InvestorsReference
2018-01-08$76.0MAAdvantech CapitalArticle